Key facts
- This page summarizes Roger Pomerantz's Form 4 filing for Viracta Therapeutics, Inc. (VIRX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 27 Nov 2024, 16:06.
Roger Pomerantz - 25 Nov 2024 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)
- Reporting relationship
- Director
- Issuer ticker
- VIRX
- Reported as of
- 25 Nov 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Nov 2024, 16:06:38 UTC
- Prior SEC filing
- 12 Sep 2024
- Next SEC filing
- 11 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael E. Faerm, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Roger Pomerantz filed Form 4 for Viracta Therapeutics, Inc. (VIRX) on 27 Nov 2024.
Change
- Previous filing in this sequence was filed on 12 Sep 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VIRX
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +9,034
- Change %
- +7.7%
- Price
- $0.000000
- Shares after
- 126,478
- Date
- 25 Nov 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VIRX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -9,034
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 18,069
- Date
- 25 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,034
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.
Footnote F2
One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.